<SEC-DOCUMENT>0001193125-11-345795.txt : 20111219
<SEC-HEADER>0001193125-11-345795.hdr.sgml : 20111219
<ACCEPTANCE-DATETIME>20111219170637
ACCESSION NUMBER:		0001193125-11-345795
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20111219
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111219
DATE AS OF CHANGE:		20111219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		111269843

	BUSINESS ADDRESS:	
		STREET 1:		10813 S. RIVER FRONT PARKWAY
		STREET 2:		STE. 500
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		10813 S. RIVER FRONT PARKWAY
		STREET 2:		STE. 500
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d271028d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): December&nbsp;19, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Lifevantage Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Colorado</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-30489</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90-0224471</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10813 S. River Front Parkway, Suite 500, South</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jordan, UT</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>84095</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (858)&nbsp;312-8000 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address if changed since last report.)
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
December&nbsp;19, 2011, Lifevantage Corporation issued a press release announcing, among other things, that it had entered into a pre-arranged stock repurchase plan under which it may repurchase shares of its common stock as part of the
Company&#146;s previously announced repurchase authorization of up to $5 million in shares, that the Company expects to receive the requisite approvals necessary to amend certain of its warrants as contemplated by its recently disclosed tender offer
to amend such warrants, and discussing its continued progress into 2012. A copy of the press release announcing this news is attached as Exhibit 99.1 and incorporated by reference herein. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release issued on December 19, 2011.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-2-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;19, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lifevantage Corporation</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Carrie E. Carlander</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Carrie E. Carlander</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer, Secretary &amp; Treasurer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-3-
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d271028dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g271028g53i49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIFEVANTAGE PROVIDES CORPORATE UPDATE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;Announces Adoption of Rule 10b5-1 Stock
Repurchase Plan </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;Anticipates
Approval of Warrant Amendment to Remove Price-Based Anti-dilution Provisions </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;Outlines Operational&nbsp;&amp; Strategic
Accomplishments and Guidance for 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Salt Lake City</B>, <B>UT, December&nbsp;19, 2011</B>, <U>LifeVantage
Corporation (OTCBB: LFVN),</U> makers of Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Nrf2 Synergizer&#153; patented dietary supplement,
announced today that the Company has entered into a pre-arranged stock repurchase plan under which it may repurchase shares of its common stock as part of its previously announced authorization to repurchase up to $5 million in shares of its common
stock. LifeVantage further announced that it anticipates receiving approval to amend certain warrants to remove the price-based anti-dilution provisions contained therein, reiterated fiscal 2012 revenue and operating income guidance and outlined
expectations for continued operational and strategic progress into 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s stock repurchase plan will operate in accordance
with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934. Accordingly, transactions, if any, will be effected in accordance with the terms of the stock repurchase plan, including specified price, volume and timing
conditions. The shares that may be purchased under the stock repurchase plan will be applied against and subject to the conditions of the repurchase authorization previously announced by LifeVantage on September&nbsp;6, 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Douglas C. Robinson, the Company&#146;s Chief Executive Officer, stated, &#147;We are pleased to announce that LifeVantage has entered into a Rule 10b5-1
share repurchase plan, under which we may repurchase shares under our previously announced Board-approved repurchase authorization of up to $5 million in shares. In addition, as we look toward the end of calendar year 2011, we are proud to reflect
on the significant improvements and accomplishments LifeVantage has made over the past 12 months. We will enter the new calendar year a much stronger company with significantly greater financial stability and operational maturity as compared to a
year ago.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Offer To Modify Warrants </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">LifeVantage recently filed a tender offer document with the SEC and initiated a tender offer for the purpose of amending certain of its warrants to remove the price-based anti-dilution provision contained
in those warrants and to extend the period during which those warrants may be exercised by 30 days. The Company expects that as of 9:00 p.m., Eastern time, on December&nbsp;29, 2011, which is the time the tender offer expires, it will have received
the requisite approvals such that all of the warrants covered by the tender offer will be amended. If these warrants are amended as expected, the Company will no longer be required to account for these warrants as a derivative liability as currently
required under U.S. GAAP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">With this expected effectiveness of these warrant modifications, paired with the expiration of certain other
warrants in March and April 2012, the Company will be removing all derivative warrant liabilities from its balance sheet and eliminating the quarterly changes in fair value of these warrants from its income statement. With these changes, the Company
believes that its financial statements will more closely reflect its operating performance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operational and Strategic Accomplishments
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">These expected improvements to the transparency of LifeVantage&#146;s financial statements will be the most recent step in two years of
concerted efforts to improve the Company&#146;s financial performance and stability and to position the Company to support continued growth. In early fiscal 2011, the Company achieved positive cash flow from operations. Since that point, LifeVantage
has announced sequential growth in both revenue and operating profit in every quarter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, during the quarter ended June&nbsp;30,
2011, the Company elected to redeem all of its outstanding convertible debentures, which resulted in holders of such convertible debentures voluntarily converting their debt into shares of common stock. This eliminated recurring interest expense and
removed all long- and short-term debt from the Company&#146;s balance sheet. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g271028g53i49.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the recent first quarter fiscal 2012, the Company&#146;s revenue increased to $20.1 million, a 214%
improvement compared to the prior year period, and its operating income improved to $3.4 million. LifeVantage also ended the first quarter fiscal 2012 with $9.4 million in cash, an increase of $3 million from year-end fiscal 2011, and no debt,
demonstrating its ability to maintain strong quarterly revenue growth while increasing its operating margin and building its cash position. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concurrent with this growth, LifeVantage has been making significant, strategic additions to its management team over the course of the past several
months, including the appointments of Douglas C. Robinson as Chief Executive Officer in March 2011 and Dr.&nbsp;Joe&nbsp;M. McCord as Chief Science Officer. The Company expects to continue to add experienced and strategically important members to
its team, with a goal of driving continued and well managed growth. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Douglas C. Robinson, the Company&#146;s Chief Executive Officer, added,
&#147;Calendar year 2011 has been a tremendous year for LifeVantage, and we are excited to continue that positive momentum into calendar 2012. Making the necessary improvements to our financial position by reducing non-cash, non-operational expenses
is a key hurdle we need to cross in order to take our company to the next level. We believe that the strong performance of our business was not fully reflected in our financial statements, and we recognize this masked our operational results. We
appreciate the loyal support of our shareholders throughout our continued efforts to improve our performance and results.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fiscal
2012 Outlook </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In support of its strategic and tactical business plan and progress to-date, the Company reiterated its previous guidance for
fiscal 2012. LifeVantage expects to generate revenue in a range of $95 million to $105 million, a significant increase from $38.9 million in revenue in fiscal 2011. Further, the Company expects to generate operating income in a range of $11.4
million to $14.7 million, and an operating margin of 12% to 14%, which represents a 250 to 450 basis point improvement from operating margin of 9.5% in fiscal 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the remaining two quarters of fiscal year 2012, the Company&#146;s financial and operational goals include significant investment in its infrastructure and increasing personnel in corporate
administration, finance, marketing, operations, sales and R&amp;D. This will provide the necessary platform for the Company to continue its organic growth and to position it for entering new markets. Additionally, LifeVantage is looking forward to
continued scientific publications, and to introducing complementary products to its markets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In its dedication to continue to expand and move
the Company forward, the Board of Directors recently nominated four new director candidates for election by the Company&#146;s stockholders. If elected, these directors would add diverse and deep leadership experience to the Board. The Company
believes that the changes made and underway will position it as an up-and-coming company to watch in its industry and a credible leader with a reputation for strong operational and financial performance. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">And finally, this outlook for fiscal 2012 underscores the maturation of the Company and its improved position as it considers a move onto a national
stock exchange listing. Against the backdrop of measured operational performance, an improving balance sheet, enhanced corporate governance and investor communication, the Company believes that listing on a national exchange would be a significant
enhancement to shareholder value. The Company expects that once all derivative warrant liabilities have been eliminated from its balance sheet, its stockholder&#146;s equity would meet the minimum requirements for initial listing on a national stock
exchange. In that case, the remaining initial listing requirement to be satisfied would be to meet the minimum share price requirements. As the Company evaluates the benefits and optimal timing of listing on a national exchange, its management team
is considering various alternatives, including the possibility of seeking approval for a reverse stock split, which would significantly accelerate the Company&#146;s ability to meet the minimum initial listing requirements and achieve the benefits
of listing on a national exchange. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Robinson concluded, &#147;We are very excited about our outlook for fiscal
2012 and beyond. While we have grown rapidly in the last couple years, the opportunities ahead continue to be robust. We look forward to achieving strong growth and profitability while continuing to help many people improve their health and wellness
through the science of Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR SOLICITATION TO MODIFY ANY OF THE OUTSTANDING WARRANTS OF LIFEVANTAGE CORPORATION. THE TENDER OFFER DESCRIBED
IN THIS PRESS RELEASE IS BEING MADE ONLY PURSUANT TO THE OFFER TO MODIFY AND CONSENT SOLICITATION STATEMENT IN RESPECT OF WARRANTS DATED NOVEMBER&nbsp;29, 2011 (THE &#147;OFFER TO MODIFY&#148;), AND RELATED MATERIALS THAT LIFEVANTAGE CORPORATION HAS
</B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g271028g53i49.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
DISTRIBUTED TO THE HOLDERS OF SUCH WARRANTS AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. HOLDERS OF SUCH WARRANTS SHOULD READ CAREFULLY THE OFFER TO MODIFY AND RELATED MATERIALS BECAUSE
THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE VARIOUS TERMS OF, AND CONDITIONS TO, THE OFFER. HOLDERS OF SUCH WARRANTS ARE URGED TO CAREFULLY READ THESE MATERIALS PRIOR TO MAKING ANY DECISION WITH RESPECT TO THE OFFER. </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About LifeVantage Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">LifeVantage, (OTCBB: LFVN), makers of Protandim<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the Nrf2
Synergizer&#153; patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to visionary science that promises to transform wellness and anti-aging internally and externally with products that reduce oxidative
stress at the cellular level. The Company was founded in 2003 and currently has operations in both Salt Lake City, Utah and San Diego, CA. For more information, visit www.LifeVantage.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This document contains forward-looking statements made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as &#147;believe,&#148; &#147;hopes,&#148;
&#147;intends,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;projects,&#148; &#147;plans,&#148; &#147;anticipates&#148; and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not
forward-looking. Such forward-looking statements are not guarantees of performance and the Company&#146;s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the
Company&#146;s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company&#146;s actual results or outcomes to be materially different from those
anticipated and discussed herein. These risks and uncertainties include, among others, the potential failure or unintended negative consequences of the implementation of the Company&#146;s network marketing sales channel; the Company&#146;s ability
to retain independent distributors or to attract new independent distributors on an ongoing basis; the potential for third party and governmental actions involving the Company&#146;s network marketing sales channel; the potential for product
liability claims against the Company; the risk that&nbsp;government regulators and regulations could adversely affect the Company&#146;s business; future laws or regulations may hinder or prohibit the production or sale of the Company&#146;s
existing product and any future products; unfavorable publicity could materially hurt the Company&#146;s business; and the Company&#146;s ability to protect its intellectual property rights and the value of its product. These and other risk factors
are discussed in greater detail in the Company&#146;s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk Factors&#148;, and in other documents filed by the Company from time to time with the Securities and
Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date
hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>### </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact:</B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Cindy England (801)&nbsp;432-9036 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Director of Investor Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">-or- </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">John Mills (310)&nbsp;954-1105 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Managing Director, ICR, LLC </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g271028g53i49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271028g53i49.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,`#=`P$1``(1`0,1`?_$`+<```(!!`,!`0``````
M``````@)"@$#!@<"!`L`!0$``@,!`0$!````````````!08"`P0'`0`($```
M!@$#`P(#!04$"04````!`@,$!08'`!$((1(),1-!(A1183(5"G&!D2,6L<$7
M&/"AX4)28D,D)H)5-ADI$0`!`@0$`P4&!`,'!`,````!`@,`$00%(3$2!D%1
M$V%QD2(4@:&QP=$R\.$C%4*2!_%2@K(S0Q9BHM(F)#1T_]H`#`,!``(1`Q$`
M/P"?8"J@@(@4-P`0#[_V?PUZIM"7`2<(I"UE)YQ4#'$"=W00`!^'41Z]=0R<
M4$Y3B0)*03G*+G><1'H'PV_@&K2A!&,?`KU$"+"BH"/88`W`0-L)P(4>TIC%
M#J4=_01_].J)R6&D\3$O]M3BLA$)[R+?J5<_T;D+=\+<):SCXM>QO9WU0?WF
M[5=U>'%SFHU4R,@>$K[&0B3-6"2Y1334!PJ=0Q1W(778;+_3FVOT":JXDA2Y
M&04!*?.8CEMQWO=4U#B*!*.DVHIFH9RY`&&^^";R0<E/(3BS.4YR7KM:A+7B
MN_0=7BUJU4Y&G-I-A*P*<LJLM%2+EVH15NJ?V]RJ&`0#??X:5MV;=MUI=0BA
M42V29S4%<(9-M7VONE.IRN0`L'`R(GVRY0^@IMQ`P@`B/3M^/4-_W[:2EK#8
MTIQ(AM0@K\ZL!'(QA[@*4H#Z@']_\=2Z:%IU*SB*EJ2J0$?"<Q=O3UZ_<'Q$
M?7TU!"6VYXY1(E>$?&5$O7I]W3^SKJ:4ZCK'VQXI13@<XIW'W]?W[!JKI'K:
M_P"&)%4Q(9Q4IS]>@;]>GV[;_P`-]M>J2$`J1C'R2HX*PCD!S#\`+]N_P_?J
M0(#86N/3]TDY19,J<1W`2B&X`&W4/0.NVWVZK6KRA;8,S$D(*B=60BH*J"8P
M=H;`.P#^X/VZM+*4@*'WRRBD.**B/X9Q4#G`=S=!V$>H=!+]VWJ`;Z\0HJ!!
M&1$3((DKA'Y$_.,X"'?SL@82,(ADZDGHE(!U`:M$#K+"F`F*`'*F41#[?34J
M9M3SO23FK"*WW4,L%YP32(TAQAY-8UY;8GB\U8BD'4G2):>ME>9N7K4&K@\E
M3IY[6YL@I`LJ!2MY6/53`>[Y@+\-:*VB%)4>G5G*9\(IHZHU;!?29-SE!#BH
M;<!^78/[^FLBU%!TC(QJ$SC'P+"(@&Y?]/XZB%*GC'P.,<N\V_P'[OA^S?5F
MA$?>;5*+9%3&(/0-P`>GV_=_#7A;#+<TXF(I65JD<(Y%5'8`Z>G3_3XZ^$I>
M;,B?C'L\2!D#%0.8-^OJ.^O4I"4@*CZ<<>\W4!Z@([A]H?'^.^O5M!Q,CG$>
MHI"I_P`,5$XB':&P=/AZ@'^O[->)``DG,1(J).,5[Q`/V!_J^']FOBD%4E'A
M'VHA.$6O?'\7:&X=/7[>O]VI^F;BOK*EE"0^)'G9XM\PN4$3Q4Q[6<@1E\F'
M%U19O9Y@@A%%&C1\K)2(JJHJ&-NNA$*@38-]Q#[=-5ZVC56JB36/&85+WPMV
MO=3-95FBEI7YN&<LS#O"^A=S"?T^;M'YNGJ(;=.FE0(2GOAH4>H2I.4#;R\Y
M.4OAUQZR-R,R*RE7].QK&(RTPUA4B+2:[9=XW8D*T2,($.H59</Q?#1&UVU5
MTKDT:%2*XPW*YHM=`Y5KD-(P@1N%7DXPWY&L.9SO&%(JU026+(]_$R0V=JBU
M<&D)"O23]DY9?3F.`F1^EV/Z;#]VB5SV\[8;HPVZ9ZE`^R<!K;?V[U:WW48:
M01RQER]L0%_'3R%X[<9?(;8<[<JZPXN%&K\_DIW'1Q8=K/F0N4A+OT(V6^A=
MD6054;&4%0IA`3$.`&#80WUVV[6NIN-B])1*"%E(E/\`$XY-05K-#<$U]8CJ
M4Q6J8`!(/./0"\>7/GB9S?IN5<D\=*[_`$7!T6>CXJ^2$O!QE7!R\-$@_;O7
MCA$B"2Z+2.``]Q8WR%#;<`UP^[V:Y6MU--4JUNK,A+&.NV>\6RXM*=I$Z&T)
MQGA*``Y6?J3>%O'R^S&/J,RL.:9:O/S1TU-U4&Y*L1V@8R;ILPE7BK5*0%!<
M@D%1$RB1MMRF$.NCUL_IU<*IH5%2H(*A@#V^Z!%PWW2,/^GID%:`J1/"?+$P
M0O`[SK</.<ML:8PBI1]B[*K],XQ55NYD8Y"P+I[&,R@I<YQCGC[VS!VH>][J
MI@$"%-MK!>]FW2TI+P!<ITYD#+AP[X(VO=UOKW_3*&ATY3X^W+@>,,'Y`\N\
M,<8K!B6`S#..H`^:KLPH-,E!8NUHE2S2BGM,(V3D&Z"K2.^I5$"@=<Z9.OKI
M=I[2Y7(6NG$M"23[!.#57=FJ!2$U4CU%`)]ID()\IBK$3$IP[1*00,7<0ZE`
M2]FX;&*8!ZC\-8O,T>EQC>"AT=0XB,%R?DRI8=Q_<,G7Z70@Z?1X9Y/V"57`
M?:8QC%/W%U/E*;W%0,8"`4-Q$?OU92T[U0X&DB9)RBFJ?;I6NJK`"!*G/)5Q
M$J''.E<HKSE2,HV+<CL!DZ.O9DG+2QVAK]6JS3/"58&YK#(D660-\R38Q$R"
M!S"4H@.MU/9JQVK-.TDJ`S(R'?W1B?O%&RR''%#41.`4)^H;X)C(D3>(9@C*
MJNZ*U)?W^,+<A4C$45*F"Q9%2#*04MAW$?@719S:E26YEUI2Q_"#YB>4H$-;
MKIG'"@(6E(/W'(]HAP^&\W8KS[CR%RCAN]5_(5&L#7ZJ.L%>?I.T#E`O>9L\
M2*/NQC]'_JH."I*ICT,4!TO/V^HHZCIO(4V>2@>/$3X'LA@I[BS6T_4:6%CF
M)?*!;=>2[B+'4#-&2I[*$96:Q@?(C[%5V>395VC@UY91K.5_(X-B*/UD^^<L
MGZ9TDV::YC`(CML`[$QM^X.U"&])DM$PK&0Q(QC!^_4C;"]!&M*Y$83R$`O'
M_J$^%QIQBSM=7SQ0:E(/4FC/)]RQ3;HJBN4W"J:2+M.55A"D,U7`P&*)?F`.
MH@`:WO[3K*9O676UJ_NISC"UNRE<=#3C3DCQR&$-PLMXJ&2<"VJ[T.PQ5LJ-
MBQ]-R,)-PCUI(1L@P<Q"YT5V[I%4Z9Q,!MQ#?N((;&`!Z:"4].[25S:%I(=U
MC`]\%7JINHMSBV5`M:3AARY\_?$7SQ*^7CAWQ(X:06$LMV.V,KU6\K9S?RC6
M*I5HF&`(V'*-BFXX49*+AWD>L9PR>$4-VJ#V&'8VQMPTZWK:U76U?72ZVC]-
M)QP.`Q]T)]JW+1TC!9"%+DLX`\S\HDK8MYC8)RGQ\3Y0Q]R9UO"YF3^0=6JZ
M=U6;1K2,=JLG2LA^=$8&;F.Y3$B93``J#L!0$Q@`49ZA=2]Z=)"G1Q'RAVI[
M@S44_7EH;XSX0MVW_J!.!<%,O8NH/\G99:1:IDY"PXZQS;9B"0,4X$,)GQ84
M$Q(4#;]Q1VV#??;KHZSL^M<9ZKCK:-0P!S@._NBB:=+;:%+*<Y0>/$CG]Q>Y
MMP\A(X$R9&V&4@^T+#4G@+Q%QA143[RB\@)-)G)G13,'899-(Z/=T[M^F@UT
MV]7VPH6[,TYS5P@A:[]07+4ALCU(R2<#*"6O^1Z1BBH35_R3;82D4RN,57\S
M8;$_:1<6P;IE$W\QV\422.<P@()IE$3G'H`"/369JEJ*A:*:FFIPG'\<(U/5
M5/3(545$D-@83,C"5)G]0WPB:V%Y'UJNYPO]6CWJK1?)%0QA:I"D`FBH*:KX
M988<$R-DS%'J;8>T.[T'?3.C9=P=3K4XV@@8))$X7'-WT33X90RXM)`.H990
M<J7DXX=RG&B9Y7P.5XJP8FK+J-865S$)N'4Y7)63=HL&L9.0`(?F\6Y,Y6V+
M[Z!"J`41((E`1`=_QRZJN'HDIFJ1X82[X(_\@MIHA4J,E*.`GE!NQ]M@WU3:
MW@T@W8UIY!(6/\SDUDF+5K#JM"OOK':SDR235-)J/>H902D('41#05=._P"H
M+"!^N%Z2.Z#1J:84X?69-:)SPA-.3?/;PJHUTFZI26&7,Z)U]RLSL%FPSCJS
M72K1+Q!0Q%D5IB,B'+,Q$Q`1]TIS(F`-RF$.NF5C:->I(0M26E+&KS?B4*[^
M[Z%I94@*=0@Z?++^V#WXD\Z^-_-FJ.;3@:_L;`YB%BMK54'Q5(BY55V.X?33
M==D4V<F@CWB&RX)"D8P@!3".^PBY62OMZP'Q-'!0R/RP@O;KW0W%!+)`7A-)
MS$&%N7M'_AW#K_O[]P@)MOP^O3[="^M_!QR@OT$SG'FO>!ON5\V..A.&Q4Y3
MD6`;;[[_`-)7C80$1$-A+OOOON.WV:[YOO4K;87_`'0CX".([>*G-V%*\D%P
M>.)/TCTHP$P>NP_-OZ@7I]FVN!D/".W(4D:I0G;SXD__`":Y>F$=]Z9&@(==
M^T;'%?,7K\IMQ]?38--^QT_^QL!>>,X3]Z:3MYT\`H?&$L_I:2@7BKSN]"]D
MVS[2AW"4=Z5/[]#&'H81'?39OX3O=(D_:=(_[I0L[.2C]NK%()TZC+^6$5>*
MOB!B?G!Y%[?@G-:,LZI#D<HV,Z4*^"/>%?QDP\^G,FN8BW\L@&W[1`=/%[N#
M]KL9J&"-:4B7PA4M-(W77!-(\9LJ)RPE,^_&'H>7'&N(/"_P0D./7$![9JQ+
M\T\EF9V:3?31G4FPKU7@"&F%&:Z*:"C8DBT$&X&#J!@'K\-)&TZAS<UT747!
M(DR!+CYC^4-FX:)K;U$*6C44J?44SY`"<S'Y/A$\(?&W+'&6M\H.6<1_6T[E
MDTQ(4NCOI1>/C(FK-GZT:PE'@-G"#US)2X,SNR"*A0!-4O0?4;MV;LKJ*M]!
M;P0E"@"99GA*,FV-L4=;1JK+F9B9D)RP!X]_;C`!><OQLU+QM90Q#R*XJ2\E
M7:!;[#VQ;!"0%V\H>18(Q)>/1CGR9_K`8R;=NH<.\QA`$C%WV';1W:M\?OM&
M];[HD]4`3PP4#B/>('WZV,6)\5%O<`IG,1Q*5"7&?$&)!>96$AY9?!]4LN0"
M2KC,4'0&64*NZ8@4TJVR5C4QEWS=HH0O>C)2!(X0(!0[@,J'QT@A*;'N5RAU
M`T[ITGA(*[YY0X+5^][;16Z3U6TDI/,I$Y^Z&M^.KD]'\O>'>$LWH+I*3,W4
MV<=<DD/PLKK"-D6%G9^V)A,D!))(XE*;<=M*M]HE6^Z%`Q0K[>T'M[(9;%6B
MMM04)S`\Q[>/C"^_.E>+#>,9X)X(8Z<JAD3F;E*+J;MLU4.1RRQM7%DI2ZR*
M_MF(9%H+<H$[S?()A`-']I,MI><N#P_19'\T!MU5*BRW0-`]9XY\N\<88O-<
M)^+<O3L#5[)&,J9;X?C=68J$QW_4K-%6*KY(^%8PJSX[`3)QS@SM)D90Y5TU
M$Q4$3"7<=]"$76X"I>]`=/56H@2F<22!/ND(*+M5&FG:]:)Z6TI/`9`?'&/V
MY4O"Z6C'&/)-GQ[>1RR"D>M6%(BB"D1)4@I'0*Q28D30,=,=@,0I3%'J`[ZI
MIV+\A\/EMQ+TYYDF>?MB=0[8O3^F);T2E.0'O^<)OX)5>#X8^5SDKQ#Q3*$_
MR\YJQ8QY#8\J3-\9]#U"<7.Z;V"-B2^ZJFUCS+MC=I0V^7;<1'J+A?!55UDI
M[G<!*N#A2J8D9`X=V$H5;*MFCO3]#1J*J0MA2>0)!F.W&`[\6O#*"Y-\].=N
M0,RMBVK#6"^3-@E*)CR4)[]6D\P6)JP2F+'-1AQ^DE5(.MQ$<FU(L4Y""H?H
M.XZW[DN[MNMU-34\@MQA)GQQQC%MVVBOKZEUY7D2^K#NP^42G[]Q_P`,9.HL
MKC:ZXMHTY3I>(<1+N$<5>$*R2:.$CME`CRI,DSQ[A-,P"51`R9DQV$H@.N;,
M7&I9?2Z%J*@9YD^/?'17+?2NTZD!*0J4LA.$%>*\9S`<UY.>`#R4?RE2XW3;
MV>Q%^9N%G:D30KI'2CDD20RYSG^G8N3HD*&_X0Z;:>KVRBH]#=D22Z\M*3AV
M3G"/:G2V*RA4%$H;)S[991NOP*XHQ?:?'+29BR8VQ_99E?,'(E!65L-+K4S(
MJ)M\QVM%NFJ^?QB[M5-!%,"$`QQ[2``!T``T"W54U7[H4I<4GR)&!/*60,']
MLT=)Z`K*4ES4K,`G,<93AQ]^P7B')F+9W#-OH5:=XMLC0K*8I;2-:Q,`]9`\
M3>`E]#%%9)(',\0`QA)V]0W^.@#50XR[-LS<'M@R]3,O-:5>5LX<HU5!U3A3
M@Z)8T6(@,!T6,CVP,$(=2*IK94$$"`G[;I1=J9X]4#<`,9<ZB@[^NM^B^5OZ
MC:75I["1EV9>$#P;+1G02V#VR/X[H2!Y":!B'B+RYX1<\^*ZE5J3BY9U@\*9
MNAJ`X8LJ[=ZA>5$FZCMY#Q9B1Q7:15C)E,1(NW=W!L8`'3;:!6W:B>L]Q"M*
M$3!(Q'9.%6[(H[9<6KK0$)*C(XX''ER,9/S0BWGDH\H=!X#R<K*->,_'+'L7
MF;/<'&/EFJ5ZL\VF@_KD!)G;F3,I'I,721#(CN'N@<1^P,]L#-DL*KBH:JMP
MR3_TXR!GQGG&NXZ[[>O1I6$T[(!4F1\T^'9#\JA@/"-%J3"C5/%>.X2H1T:V
MBVL$UI]?%H+-J@5NDDZ*I'G!\(I$#O.MWJ*#U,81$=)[U;6ON=9:W.H3/!1`
M_+V0W,T5%3HZ24(TRE(B9\8BO>?_`(!1F"<+VSD]Q>1)CJK72;K57Y'XRKZ8
M-:5;HY[,ME(2V-:\AV,HZ:A94B8"=`A2^TH;<NV^ND;'O2G:E=/4R-3H.E1Q
MEW\XY]O&RML4H?8F&0H$RGQ/"#!\E>1[_DVG<`_&_B2Q2-7F.8:%5890L<,J
MHG)0N%X"'CW=Q43<)'*JV,XC$5C&$HE$Z8"`;;Z&6N@3ZJON[V`IU*.69[(V
M7:K/IZ.UL8]4)!QR!XGOATV`N)_'[C3C>!Q3BO&U0@Z]#1J#!0XP42XDI@R:
M8$7=34@NV4=2;EP?N,85C'VWV`-)MRO%TN2S5*<*4C`#$2`/?#;;[1:K>V&0
M@%PB9F)S)X_E",/)EBB%\=G*/CEY'N/L(TI,-:,IUO#G):J5A`(JLVRN7=TC
M&1D^[AV0IQZ3R..7O,<B90_D]VP"81%NLU<[>+<JV5P"E(3Y59RGSXG(?G"K
M=:-FSW!-PHQI"U$*'.4LNZ9B27^=Q?Y*-A]\/R;\N":!YW?RQC/HQD!<=_I[
M(,]E=_LT@])7K>EAU->GLG](>?4)]#ZG&6F<N.4_AQCS>/`LJ!O-;C[;T+*<
MB#;_`'&J-Z`!^_?7>=\K!VS(9D-R]T<:VXYKW4L_P:G)'GG'I0_A$``0$##W
M#\1V'_=^``.N!#K$DC[>$=M0EM0))$X3YY\-@\3?+PO3_P"&1?7T#<UDBQVW
MW]`#3=L<D;G8U\?SA5WBA)V\Z$D9CXPES]+:3NXL<[^W_P!Y9_Q_HJP&V#?8
M-]@TW_U"\MZI"G[M2?\`.(6-EH!H:M`/%7^6%G_IZ0+_`/;]/&-\(/,`AT$0
M'MEW8&WV#T`!TR[P/_K!(S*4P!VTP1?FI]ON)AAWZN2ORWTO#.XBBL:N$E,@
M5E51,!%!O-*,2210,?T3,JT-MU#J'32U_2]2$+J`K[\#[.?C#'O\)6]3<4)4
MKVX'WP%'"GQ`^1OE%QKQ?FO!/-J*K.+[7$KA7:JE>;(S-6213QS%O()5FTAU
MT&3ED[:*$.F4Q@VVVW#81*WW<EEMMT73U=-K>$B"0,>Z%RS[>O=RI"]3/!%.
M5'RZC@)\1*-YW_\`3A>2S),8QBLF<P*!<HAM().V$9:[A99!B23*DY;H*M4W
M4`!?JP;+J$+M\P@<^WIURM?U!M+:B:>F4%\9`>^4$QLRXE(ZSC9EE,F7OXQ*
M`\4/#"_\%N%U.XUY1L4!:[%79^UOWLC6E'"T(I'6!RV4;-$?K&S54_M))G`^
MY``!'XZYON"[HN]W5<&!I00/$90_66TKM]L%$\H$S,^4CR@(?%VW4X>\V.:G
MCSE%18U5Y8G')/`B2I^QO_0EU=J+S4/%D-VE.6!=JF*H!0``*7?;;1V_H;N%
MHI[HF14V`D]Y^<X!V-:K;<W[2J80X2M/=](KQK3/SB\P'(;DJX#Z_$7"6M-^
M.>*%C_S64AD1^HK-7650'YD_JH]20.D8Q?5(4^O3;5%:?VJPM4J,*A[[^<NW
MV81;1(1=;X[4JQIVOMY'NC`>3*V8_)AY&[WP,@<HVC#_`!>XV4^OVC.#JDOE
M6%JR%.V+YHVK)/DSI`P8F*'<90P*;$*8O:/?N&RB-!9;"+DML.5JE8$^,45"
MJR[7LV]"B*1*<2#@((Y/]/[XY!B@:*XZLRDF"92&GS6EP676<``_]ZNZ!L81
M<]P=PFV_%H:YO&M6^%A*1,SEQ@BSM.D2T4K65%(^['&`;XM\1<=<,/.`UQAC
M2XW>UUU[Q%D['[5XL!['(UI9Q(S"2,1'N%$D3-XD42@<I-MP,/IMUT?N58[<
M-K-5;B9.*?4".Z0A>M]*U1;F=IFC-(92?&9@L_"$'_D_DT5$A04_SW7(ACIE
M`RBH?T53]NX=PW$"@`CUZ"(Z%[U&I%"`<F$D^$%-FI`<JRK/U*Q\(?2.Y?FZ
M_A'<.FP]W0@%#?H.X_-^S2(V)(*?]PS([H=5:@0K-..,1Q.-!C!Y1/,Z(]"C
MC.E!L&P[;1IPWZ==Q`==">65VJVHY.I^$(;:$IN5:X/O4R1+_%!$_I]P(;QI
MT8#&Z#F3DAOU^4-LSVT0[_@8@_'0'=<_W4@?=I3!W;82+>5$Y+5\HKYC>2^:
M:#$\=.)W&Z:&J9KYFY(&A,KXDJ8AZ53XA)LI;)-H9,"JC+.&\B0&XAV]I4C@
M(^F^C;-`P.M<JI.M#"9Z?[W",VXJM]19M],9%Y4ICAQ^48S1_`#PE0@4E,U&
MOV>,D.4"*V:_7.VNU7\I(F*4SLR)/IUQ:-@<`)DB=Q]NWUU-W<M2APFD2&F"
M92^&45-[<IW6QZA>MP"9E.%=>47Q<<=.%,?Q:R3A2=R##_G7+3$U>4H<Q;E9
M&GNP7FFBQ9%M%';I^W)QZ11$JH;B4`]-,^V+V;N[44Q0$.):Q7`6_P!G30=)
M]2]3)5@B#1QG,MN-OG\S'$7\Y8N+Y>\>Z2_Q9-O5`09RLE4XF/8R4.@NKVD%
MU^9,U4REW[A[=]NNA[],JX;52\R`2PKS@<`#G'M*ZFV[I<ZYDAY"0@GB>0\>
M,23`,`E'M'8"@`"/:&X=/01`=M]M<\*"H"2\#'2.H@J)T3,\<8C[?J.^0-+Q
M=P'G,82$@U7O>9+55(6JUX5$SO5VC"9:R4Q+G0*)E4F3%LUV]P0V[S%+\=]/
M>PK6_4W-3R`5-H09GX0E;XN+35N]+@'%D2'8#,^X3@&.?V)<B9#\B7BL@:7F
MJ7X[RE[X[S50J668N(+.+1=F/7DUPAFL>>4ARJN9Y(/I0V7*.RNP`.F*TW)M
MNV5\F^HA#KFN7('C.%ZZ6Q2ZZD=4YT^HV@([3+A!YAXJ/(&`COY<\J[;#U)B
MLG:!1_"._P#B1N)NT?F_YM]+R-VV1M*6#0MJ3+,\<>Z#G_&+D25FL<#AY'*-
M59?\''*[/U60H&9O*-D*^4A*PPED6@)3%*9T%)&ONRO6#A(Q\AJ@FX1,(@!N
MT=@..M8WE;VFE"EHDMJ(S$ORBI_9U:]IZ]:MPSF`3XQ(*_H,W^%(8U_-C^Y_
MAX-$_/?9_G;?TL%:_-Q0]S?ZC?\`G@GW>NY>[XZY]K'KO5<-6J7MG^4.WID^
MA]+/'IZ9]NG3^<>4[C2]<J^)_)68SS@6FY#JV3:O;,BLX&?4Q;+V!%!G8GDU
M$R1/H)>`?QSD',<\.4B@IF$HF`2B&OTX^W:KC:FVZC2IK0GNR$<$4^NG=-12
M:DU"75<,<R#EP]T,#)YOO-F)=_ZFNA.GX/\`+U$FVZ>G<:C"8W[QT!3MBP%,
MPA)!BY[<-]2HE+B@#EA#"ZKRWYO\WO#1Y-C\HT[/:[16D:=&4B/-C,*M)+-'
M;R%<O4&,5%0$8O+#[@=W<5-3MZAN&EIZAHK-N>C73`!I4_QXP<IZJY77;]2F
MJ)+J2D^P&?&"-_3!56WP/%OG$E9*G9:TY?S#86;6PPDI#KO0+3)]/O:-))LW
M.N`FZ;D*(B(@'V:S;\?0Y>*4C@H?YA&_9C;BZ.K=2)!4R!_A,+@_3]T:_P`'
MY;[%)3M$ND#%)PV7B)24W69N+C3"XE'7L`#UXR0;F4/W;@!C=0]-'MUU3+FV
M4I6<=(E`/:[%6-Q)`!.F8G[8F`>5O@)#>1#B;:,-&<-HJ\Q#PEQQA/."D`L?
M;H](P)(+'(4QBM)0G\E<`#8Q=M^FN7;7O8LM>'4F;*P$J[ISCINY+*;O0E"1
M)YLE2>^(0_'+G?Y)/!]8;A@J?QLI(4)I,/'*]%R1"S@4;\R64[%YRHVF,:G,
M@E(^V542-W)4U!,(G#N$==>K['M_=2$5BER6`#,=G".7T-VNNWTKIT^0SQ"P
M98\0>WEF(W!-^2?R]>6;,V+*A@R!D,:1M?MD588IAC&-GF-%C)*.=$*6=M]O
MD6J2K]DR(Z$3LW#E1)0HF[4S;:S&P;9V_3*?<DK4DB9XS&,:3?;_`'FJ;IZ:
M90#-12,!WD_`8QZ`V,FEX88ZI4?D6293%^:UN*;7"0C$BMV,A/I-TB2+A@4$
MT4TT3K@8PE[2_;MKB54NG]6M3(_2*L(ZU1M5!HD)>/ZDL80YYO8/*''2U\>?
M(WQZJDC:LD8E?S&%KU`P3!R]=3M%R>U5C6OOMX])1VX3C9`Y@..PE0)L/RZ;
MMHU#52I=LK)%A1U`'L_$YPK;K872!-RI\'@)'VP>GB:XVO.-?"_'<?96YTLG
M915D,R98?.$S)/7MZOSE29?B\]PI3@I'-G23,@&#HF@4`]-!=SUB*VYD4T@R
MW@!V9P;VY1^DMP+G^JL3G"T^4A,S>,?R.7GGM6<86K,/&#DK4:_5<ZQ](8.)
MNTT.?K(E)%V5*,9D5?.T"D4,0P$(HGV&,(AN!=,-N73WVS?MM5)%6@>3+&67
MB(6+A3U-FO/[M3**J8S"AW_G&[YK]0#Q2DHDK/"]!S;F/)THF"$+CN`QO;&\
MBK).0[$F,@Y<P[=E&`1P8"J'6.F4GQ$-8$[/J>IKJCI9;S(G!3_E-*XV0P07
MUC[>(@*^"U$Y<OO,Y)9YY5U9_`6G-?&>2N"-:C6#]S5L50:JTHPKN/!G`1.Q
M--,(M),7)07.H=01$PB81'1J\+HF=MML4:M5.EX@'MPG[X"69BL=W"X[5"3Q
M:!(RPF9>Z#R\+%<L-=L/DA-/UZ9KQ)7G%;I&'-,13Z*+*QRU,J":,A'D>H("
M\8K'2-VJD`Q#"`@`]-!=X/!::3@/3)@UM2G+:ZK_`/2OXP\I0"_R_EZ]QMPV
M$^W3YCF*&XB(`.P!\.[?2@00O7/`)^GTAO29)T*XF$&<0,>3TEY7_+.G,P-@
MBZ[=*ACJ*B+"[B'C*,DR.&OT[G\HDU4$FLFHT`^X]ASB40^&G2LJFV[!0/)^
M]MV9]B3"=24Q5?*ML_:IC#^80&G!KGQ#>)FM9.X,\Q<99.@U,?9<R?9L77ZM
M46?L-9O]/O=I?VUD9J[B8UZW-(@ZDCD(3H/:``8.[<-:[E9W+\EJY4F:D8^S
M\8Q@H;NBQ..45:?)J)'M@C>?T1DCFM@?BAY'^(5&MJ^1.,&1Y'(M8QA;H9S7
M;#=:&\=$CK*FK$RR+)^VD10B2J-41*111-P<P`.P:S6DMT%4Y::XR9>3I)Y?
M/&-=T2]64[5WH1-QE6H#GA+YQL"G?J$^(BM70-E&F9IQADYJC[5@QC(8VMR\
MXWG$B@5TSC4VD,L>3;'6W!$Z8J%,40Z]VVJ:K9E8E\IIU:Z<X@]G/O[HMI]V
MTK;6E\!-2!ES/*%0^0O)?+WGS.<6>0ZF$K[BOC!C[D[CB&QG0)2`E%K[=Y.9
MF&:DEDFS1#9NX=0L+%Q91*F98J(`!NH;AIDLU-;K,A^CUSK5MXPMWA=SOS[=
M8I)11-D2$2(_(;XZ*?STQ[3%V]FE,49YQ.H2>PWF*NF,A.5*:.DFL9HNX1*9
MRK#/50`%4@`YB]1*'4=)=FW`[9WULJ3KHW<P?"':ZVANYTZ%?;5MX@B%UU^Y
M?J&L511,1GQ?QLS8HP*$-"YOF)U2&D',>W*#9M+NX5@M'Q:KHJ28',+IO[JA
MOQ[F$='_`$VU:Q)K'E%MP&>G\H`KJ]R4I%'3-A;9PU<NV`H\E/!C)=%X5Y6Y
M1\X,KIYMY=9'L&.L?4AG&H(M:9BB-L=OBT5ZIC^'1:LF8R<GT!RX*D)^U$.T
M_P`Q]R^V[W*Y&CM;833);(GE,<_[8#W^PJ71HJ[@X55.L$@X@'E](<+S]X(6
M[E%Q1P99L0RP53E)QCC:;D[!$Z!_8[[96(R-D#5QPH<!%)*9,R!(IC[%*J8!
M,(%W'2K;KK3T-X?8>/\`\-UQ06._GS[89+G:5W"VL/LDBJ:0"CV0/.(_/7CR
MDUY*C\Y,191X_9SJR*<798]2D6*1J]ED6B14%Y*LRK..>-EV3]0@J%`%!'8P
M=-:ZK9]55/\`5M9'HUXB<0I-SBD8Z5T`34),N_MCM4WR)\L>?>?\;U3@WBNQ
M8QX[U6U,IS+6>,PU!U$-K166@B1U5:G$3<>#A4'Q3"4'"3?W`.!1`X%`PAGK
M+%06^@<%>\/4B4@#Q_$HDQ=ZRX5S:J,3IIF?RAIR?,&NJ9M=X7_HVQA)-+5'
M5L9H6X!&'6D6$I(%>%7W[3()$BQ*)]]P,<`]!T$_:T>D]3J_3TP;_<G>OZ?1
MY]7U@E38WQX<QCGI-+,<YA.<QJQ#"8QC#W&,8PL]S&$P[B(_'0_]RK@-(?5I
MY:E?6"'[70DSZ(GW#Z1R#&V.]@_\"IH_>%8A=A^\/^Q'5@N-=+_["_YE?^40
M-!1`RZ*,.:1]([:-.J#1H[C&U4K3:.?"47L>C"1R3-V)0#M^K:)MB-W/;MN'
M>4VVHFKJG"%+>45#+$S'<9X18*.F"=(9&DYR`D?='<B:[7X-%=O"P,1%H.>C
MA"*C&3!-<=MNY<C5!(JH]IA#YM^G347:A]PAQQ:EK'$DF)(IV&@4--A"3P``
MG%F.IU4B'AY"+K$%&OC=X&>,(6,9NS@H(BH(NFS-)P(''\7S=?CJ1K*E].AU
M2M`R!)(\"91!%*PT=:$@*/(`'W",@*`!UVV$.H"(;[#]WV>NJ>DD'4,XM#BE
M8'",&MV,L=7HA27>AU"V`4`*4UDK</-%VVZ"!Y!FN<-O@&^VK45]73B32U)'
M>?A.6,4.4-(]BZVE7>`?E%VI8ZH%#0!O2J54ZFD??O"NU^*A@4Z;#O\`ES5L
M!NGV[Z]76U53_K.J4)Y3/UCUJBI6)EEH)/,"7CA&:AT]-@VZA^W_`&ZK($C%
MP)CI/HR.EVJC24CV;]K[A5!;OFK=XW.H4>XIS(.DE43'*8-P'MW`=>)><95-
MN8)Y$CX1%UEMY$G`".V1^,=I---,A4B$*1,I0*4A2@4A2A^$I2E`"E*7X```
M`:]&6KC$A(2`P`BP\CF,FV68R3)L^9.""5=H];H.FRI-MME$%TCI*%V_X@'7
MJ7%M?J-DZQR,C[H@MIMV:7$B7:(P:)Q7B^MOU)2!QW0XF3,<R@OXVIP;%\*@
M]1/]2T9(K`<P_'?5BKC6N#0I]24\B3[\8I%OHD'6EE)7SD/I&:D8,?J?S#Z%
MLH^$GL_5@W1^J*D/_2!UV"X!+_E[NW[M4AYPH#97-`[Y>&7NB]++87K"0E<L
MY8^.<<VK!BR%<6C-JU,Y5]]P+=L@@9=;M*7W5Q13(*RO:4`[C;FV#UU,N+=`
MZA)EAB2?C./$H0W/0`)F>$=T"@(]1V_MZ_8/[M5K44Y"<3D%9F.DFP9-W2[I
M!FW0=.2E!PZ2;MTW*X%_![[@J0+*@7X=PCMJ2EK6D().CE/#PB(;0E14`-9X
MRQ\8Q^Q42D6A1!Q:*E6K`X;&*9NM-P,7*G1$AMR"FH^:+G)L/4-A#5K5;5-_
MIMJ6&QR)^`,4NT5,X=;B$%9Y@'XB,@:,6C%FFQ9,FS5BB3L1:,FZ+9J1/80]
MLB":8)$)L/H&P:J6IQ:]:E$*YDS,7(0VAO0A(T<@,(P5]B+%4I)A.R6,:*]F
MBG`X2;RHP#E^4Y1`04*[5CSK=X;=![M7FXUK:=*'U$2RF?#.,XM]&ZK4ME`5
MW#Z1F1HF).@@V5CV*C=F8IVK11DU.@@9,-B';HF1%-$Y`#H)``0^&LR*I]W4
MM1.KG,S\9SC0:9EL!"0-/LE](5-Y$\B>13"]TQAEWB%2*]F?$56A9-OE_"HI
MK$N-G<N'JAFLO7'#<ZB_U$7']A4T"I'[SE$1W]-,^WZ"T5E.IFO64U1/E/#+
MWXPO7RIN=,\@4J9I)QE\X$QC^HAX_0[8D-EG!'(/&62VY`;R%`DJ3(J/S2Y/
MY2[)LJ:.0]SN5#M*/9HTG8%P6DK:4DM'$$\1PX\H$.[UIF7.DXE0<3@993&?
M"-4Q49R=\R?(W$%\R/B.U<?>!6`[:SR)#5.^-G3"VYGO42?W:[)NXUPV9'-#
ML!`QDQ*42;&-ON;8P5K4UM)A3#@"JU:9'L[I<@>V(K0_N2H;J&B4TH,\<C_;
M*)."*9$$DD$R%*1)--(@$+VE(1,H$(5,!W$I"$*`!I#T)+A>,RI1GC#U/2A+
M0'E"0,(PFQXRQQ;ETW%KH5+LSE+;V5YZM0LJZ3`!Z`FL^8KG*4-:D7"M94&V
MWEI1+*9^L4KHZ5P:EM(4KN'TC)H>"AH!FFP@X>.A6*(%]J/BF3./;$`F_:!&
M[)!!,H#N/PZ[:R.O.N+)<67#VXR\8M:8::'Z2`CN$HLA6*^#\TJ$&P_,3+%=
H&=_0M/J173*<I#"X^G]X3`50P`/=OUU/K.:-$_++*)Z$:IRQGRC_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
